Fermenta Biotech Ltd

Know More
NSEBSE
Stock not tradded

202.253.20 (1.61%)

09:28 AM,21st Feb 2024

BSE : 506414

NSE :

Sector : Health care

ISIN Code : INE225B01021

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Feb 21 2024 | 09:28 AM IST

Market Cap (₹ Cr)

0

Turnover (₹ Cr)

0.00

Volume (Shares)

Face Value

5

52-WK High

0.00

52-WK High Date

Invalid date

52-WK Low

0.00

52-WK Low Date

Invalid date

All Time High

0.00

All Time High Date

Invalid date

All Time Low

0.00

All Time Low Date

Invalid date

Fermenta Biotech Ltd

Promoted by a technocrat D V K Raju Duphar-Interfran (DIL) was incorporated in May '51 as International Franchises Pvt Ltd. In the initial years the company manufactured and sold toothpaste anti-septic lotion and pharmaceutical specialities on a loan-licence basis. It entered into collaborations with Philips-Duphar Amsterdam (Solvay Duphar) and the Crookes Laboratories London. These collaborators participated in the equity capital of the company to the extent of 25% each.The company changed its name to Crookes Interfran on 19 Apr.'63. In 1964 it entered into a collaboration with Solvay Duphar to manufacture vitamin D3. To associate fully with its research-oriented collaborators in May '71 it changed its name to Duphar-Interfran. In 1976 it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976 in compliance with the FERA the foreign collaborators reduced thier stake to 38.86%.DIL came out with a rights issue in May '95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand Lacto-Calamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs.As per the Scheme of Arrangement the pharma business of the company has been transferred to a new company called Duphar Pharma India. The Company has made investments in unutilised premises at Thane to create a commercial complex with modern facilities so that substantial portion of it can be let out to earn income. The successful entry of Annual Contract with Solvay Pharmaceuticals B V of Netherlands will definitely establish as a reliable contract research organization for Duphar Interfran Ltd. As mutual consent with Solvay PharmaceuticalsNetherlandsthe company has been permitted to continue with the name DUPHAR for a limited time. It has also been decided to change the name to DIL Limited from Duphar-Interfran Ltd.With the prior approval from Board the company has acquired 990000 equity shares of Rs.10 each in Fermenta Biotech Ltd there by increase its holding to 83.71% comprising 1657500 equity shares. Subsequent to this FBL will henceforth be a subsidiary of Duphar Interfran Ltd.In 2003 the Company expanded manufacturing capacity with Vitamin D and other products such as Phenyramidol at Kullu. During the year 2009-10 the Company carried out the Drug Discovery and Development Services through its subsidiaries Evotec (India) Private Limited and its subsidiary Evotec-RSIL Limited up to August 31 2009. Through the divestment of 70% equity shares by the Company in Evotec (India) Private Limited Evotec (India) Private Limited and its subsidiary Evotec-RSIL Limited ceases to be subsidiaries of the Company with effect from September 01 2009. New projects were undertaken with Bayer CropSciences Novartis Boehringer Ingelheim and Chugai. The Company commissioned a new manufacturing facility at Dahej SEZ Gujarat during 2010-11. The Company executed a definitive agreements with a private equity investor in Mauritius Evolvence India Life Sciences Fund LLC (EILSF) on December 10 2010 for sale of 1915036 equity shares held by Company in FBL to EILSF and issue of an equal number of fresh equity shares by FBL to EILSF for a total consideration of Rs. 40 crores which was completed in Jan'11. It launched new and improved Penicillin G Acylase catalyst - Fermase PA 850 in 2012.Agastya Films LLP and Zela Wellness Private Limited ceased to be joint venture entity and associate company w.e.f. January 01 2019 and Novemeber 29 2018 respectively. The Company in FY 2019-20 launched a new product fish oil derived cholesterol for the aquaculture market it launched a new version of Vitamin D 500 feed grade powder in 2020. During the year 2019-20 the Scheme of Amalgamation between the Parent i.e. DIL Limited (DIL) and its subsidiary Fermenta Biotech Limited (FBL) and their respective shareholders became effective from September 26 2019 with the appointed date as April 01 2018. Accordingly the name of amalgamated company was changed from DIL Limited to Fermenta Biotech Limited effective on October 17 2019. On September 5 2019 the Company's subsidiary viz. Fermenta Biotech GmbH was incorporated in Germany. The Company incorporated a wholly-owned subsidiary in the United States of America viz. Fermenta Biotech USA LLC on May 27 2020. In December 2020 Fermenta Biotech USA LLC a wholly owned subsidiary of the Company acquired 52% membership interest in AGD Nutrition LLC (now known as Fermenta USA LLC). During FY 2021-22 the Company launched Vitamin AD2 for oil fortification and also developed patented technology for enzymatic synthesis of Molnupiravir.

Fermenta Biotech Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

595

EPS - TTM (₹) [S]

3.08

P/E Ratio (X) [S]

1.92

Face Value (₹) 5
Latest Dividend (%)25.00
Latest Dividend Date 22 Sep 2023
Dividend Yield (%) 0.61
Book Value Share (₹) [S]105.26
P/B Ratio (₹) [S]1.92
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal S&P BSE Healthcare ETF 0.00 105 0.02

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

199.10

204.90

Week Low/High

158.00

214.00

Month Low/High

150.00

214.00

Year Low/High

103.30

214.00

All time Low/High

3.12

442.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week20.57%%1.741.73%
1 Month29.69%%2.313.00%
3 Month29.52%%10.8412.31%
6 Month35.15%%12.0514.57%
1 Year47.52%%20.4424.64%
3 Year-25.78%%43.5948.30%

Company Info

Company Information

Executive Director : Satish Varma

Company Sec. & Compli. Officer : Srikant N Sharma

Executive Vice Chairman & WTD : Krishna Datla

Non Executive Director : Rajeshwari Datla

Chairman & Independent Directo : Sanjay Buch

Independent Director : Vinayak Hajare

Independent Director : Gopakumar G Nair

Executive Director : ANUPAMA DATLA DESAI

Independent Director : Rajashri Santosh Kumar Ojha

Managing Director : Prashant Nagre

Independent Director : Pramod Kasat

Registered Office: A-1501 DIL Complex Majiwada, Ghodbunder Road Thane One,Thane (West),Maharashtra-400610 Ph: 91-22-66230800/888

Email:srikant.sharma@dil.net; contact@dil.net

URL:http://www.fermentabiotech.com